Please use this identifier to cite or link to this item:
https://doi.org/10.1111/all.12848
Title: | Prebiotic-supplemented partially hydrolysed cow's milk formula for the prevention of eczema in high-risk infants: A randomized controlled trial | Authors: | Boyle, R.J Tang, M.L.-K Chiang, W.C |
Keywords: | gamma interferon immunoglobulin E immunoglobulin G1 immunoglobulin G4 interleukin 10 interleukin 12 interleukin 13 interleukin 4 interleukin 6 oligosaccharide polyunsaturated fatty acid prebiotic agent transforming growth factor beta tumor necrosis factor alpha allergen biological marker cytokine immunoglobulin E immunoglobulin G prebiotic agent Article artificial milk controlled study cytokine response double blind procedure eczema female high risk infant human immunoglobulin blood level infant male multicenter study peripheral blood mononuclear cell plasmacytoid dendritic cell priority journal randomized controlled trial regulatory T lymphocyte adult animal bovine clinical trial dietary supplement eczema immunology incidence Kaplan Meier method milk milk allergy newborn risk factor Adult Allergens Animals Biomarkers Cattle Cytokines Dietary Supplements Eczema Female Humans Immunoglobulin E Immunoglobulin G Incidence Infant Infant Formula Infant, Newborn Kaplan-Meier Estimate Male Milk Milk Hypersensitivity Prebiotics Risk Factors |
Issue Date: | 2016 | Publisher: | Blackwell Publishing Ltd | Citation: | Boyle, R.J, Tang, M.L.-K, Chiang, W.C (2016). Prebiotic-supplemented partially hydrolysed cow's milk formula for the prevention of eczema in high-risk infants: A randomized controlled trial. Allergy: European Journal of Allergy and Clinical Immunology 71 (5) : 701-710. ScholarBank@NUS Repository. https://doi.org/10.1111/all.12848 | Rights: | Attribution 4.0 International | Abstract: | Background Prevention guidelines for infants at high risk of allergic disease recommend hydrolysed formula if formula is introduced before 6 months, but evidence is mixed. Adding specific oligosaccharides may improve outcomes. Objective To evaluate whether partially hydrolysed whey formula containing oligosaccharides (0.8 g/100 ml) (pHF-OS) can prevent eczema in high-risk infants [ISRCTN65195597]. Methods We conducted a parallel-group, multicentre, randomized double-blind controlled trial of pHF-OS vs standard cow's milk formula. Infants with a family history of allergic disease were randomized (stratified by centre/maternal allergy) to active (n = 432) or control (n = 431) formula until 6 months of age if formula was introduced before 18 weeks. Primary outcome was cumulative incidence of eczema by 12 months in infants randomized at 0-4 weeks (375 pHF-OS, 383 control). Secondary outcomes were cumulative incidence of eczema by 12 or 18 months in all infants randomized, immune markers at 6 months and adverse events. Results Eczema occurred by 12 months in 84/293 (28.7%) infants allocated to pHF-OS at 0-4 weeks of age, vs 93/324 (28.7%) control (OR 0.98 95% CI 0.68, 1.40; P = 0.90), and 107/347 (30.8%) pHF-OS vs 112/370 (30.3%) control in all infants randomized (OR 0.99 95% CI 0.71, 1.37; P = 0.94). pHF-OS did not change most immune markers including total/specific IgE; however, pHF-OS reduced cow's milk-specific IgG1 (P < 0.0001) and increased regulatory T-cell and plasmacytoid dendritic cell percentages. There was no group difference in adverse events. Conclusion pHF-OS does not prevent eczema in the first year in high-risk infants. The immunological changes found require confirmation in a separate cohort. © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | Source Title: | Allergy: European Journal of Allergy and Clinical Immunology | URI: | https://scholarbank.nus.edu.sg/handle/10635/179580 | ISSN: | 0105-4538 | DOI: | 10.1111/all.12848 | Rights: | Attribution 4.0 International |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1111_all_12848.pdf | 375.92 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License